Notice of Change: Emphasizing an Opportunity for New Institutional Applicants in Response to PAR-19-204 Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)

Notice Number: NOT-HG-20-013

Key Dates
Release Date: January 10, 2020

Related Announcements
PAR-19-204 -  Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)

Issued by
National Human Genome Research Institute (NHGRI)

Purpose

As part of the Centers of Excellence in Genomic Sciences (CEGS) Funding Opportunity Announcement cited above, NHGRI will provide new support for high-quality applications from institutions that have not previously been funded under the CEGS program (see Related Announcement). This change is intended to be responsive to language in the US FY2020 budget to establish “Emerging Centers of Excellence in Genomic Science”, which has the purpose of building genomics capacity at institutions that are not prior or current grantees of the CEGS program.

To encourage these applications for funding in FY 2020, NHGRI is adding a new receipt date (March 26, 2020) to the existing CEGS PAR-19-204 and is emphasizing interest in applications from new institutions that are not prior or current grantees of the CEGS program through additional considerations for the awardee Selection Criteria (see below). The CEGS program will still consider high-quality applications from all eligible institutions listed in PAR-19-204.

Key Dates

Currently Reads:

  • Posted Date: February 28, 2019
  • Open Date (Earliest Submission Date): April 20, 2019
  • Letter of Intent Due Date(s) While Letters of Intent are normally requested 30 days before the due date, for this FOA LOIs are due 60 days prior to the application due date
  • Application Due Date(s) May 20, 2019; May 18, 2020; May 20, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • AIDS Application Due Date(s): Not applicable.
  • Scientific Merit Review: Standard dates apply
  • Advisory Council Review: January 2020, January 2021, January 2022
  • Earliest Start Date: Standard dates apply
  • Expiration Date: May 21, 2021
  • Due Dates for E.O. 12372: Not Applicable

Modified to Read:

  • Posted Date: February 28, 2019
  • Open Date (Earliest Submission Date): April 20, 2019
  • Letter of Intent Due Date(s) Letters of Intent are normally requested 30 days before the due date, for this FOA we request letters of intent further in advance (60 days) if possible.
  • Application Due Date(s) May 20, 2019; March 26, 2020, May 18, 2020; May 20, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • AIDS Application Due Date(s): Not applicable.
  • Scientific Merit Review: July 2020 for applications submitted for the March 26, 2020 deadline; November, 2020 for the applications submitted for the May 20, 2020 deadline; November 2021 for applications submitted for the May 20, 2021 deadline. 
  • Advisory Council Review: January 2020, October 2020, January 2021, January 2022
  • Earliest Start Date: Standard dates apply
  • Expiration Date: May 21, 2021
  • Due Dates for E.O. 12372: Not Applicable

Review and Selection Process

Currently Reads:

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NHGRI, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

  • May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
  • Will receive a written critique.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:

  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.
  • Compliance with resource sharing policies as appropriate.
  • Program balance.

Modified to Read:

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NHGRI, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications:

  • May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
  • Will receive a written critique.

Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:

  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.
  • Compliance with resource sharing policies as appropriate.
  • Program balance, including whether applications are from institutions that are not prior or current grantees of the CEGS program.

All other aspects of PAR-19-204 remain unchanged.

Scientific Research Contact

Currently Reads:

Scientific/Research Contact(s)

Lisa Brooks, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: 301-547-1387
Email: lisa.brooks@nih.gov

Anjene Addington, Ph.D., M.P.H.
National Institute of Mental Health (NIMH)
Telephone: 301-443-9869
Email: anjene.addington@nih.gov

Modified to Read:

Scientific/Research Contact(s)

Adam Felsenfeld, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: 301-480-2269
Email: adam_felsenfeld@nih.gov

Tara Dutka, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-451-3074
Email: Tara.dutka@nih.gov

Inquiries

Please direct all inquiries to:

Adam Felsenfeld, Ph.D.
Division of Genome Sciences
National Human Genome Research
Telephone: 301-480-2269
Email: adam_felsenfeld@nih.gov